Ralliant (NYSE:RAL) Upgraded to “Buy” at Vertical Research

Vertical Research upgraded shares of Ralliant (NYSE:RAL) from a hold rating to a buy rating in a research note released on Friday, MarketBeat reports. Vertical Research currently has $45.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Barclays lifted their price objective on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Royal Bank Of Canada upped their target price on Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Citigroup upgraded Ralliant from a “neutral” rating to a “buy” rating and raised their price target for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Finally, Truist Financial assumed coverage on shares of Ralliant in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.30.

Ralliant Stock Performance

Shares of NYSE RAL opened at $39.50 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 1.03. The firm has a market cap of $4.46 billion and a price-to-earnings ratio of 31.10. The stock’s fifty day moving average price is $51.52 and its two-hundred day moving average price is $46.72. Ralliant has a one year low of $37.27 and a one year high of $57.02.

Ralliant (NYSE:RAL) last posted its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. Ralliant’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 annualized dividend and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is 15.75%.

Institutional Investors Weigh In On Ralliant

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Dodge & Cox acquired a new stake in Ralliant in the second quarter valued at approximately $523,571,000. Viking Global Investors LP bought a new position in shares of Ralliant in the 2nd quarter valued at $257,200,000. State Street Corp acquired a new stake in shares of Ralliant during the 2nd quarter valued at $213,096,000. Flossbach Von Storch SE acquired a new stake in shares of Ralliant during the 2nd quarter valued at $198,077,000. Finally, Norges Bank bought a new stake in Ralliant during the 2nd quarter worth $108,453,000.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.